Is Cellectis Sa Stock a good buy in 2025, according to Wall Street analysts?
The consensus among 1 Wall Street analyst covering (NASDAQ: CLLS) stock is to Strong Buy CLLS stock.
Out of 1 analyst, 1 (100%) are recommending CLLS as a Strong Buy, 0 (0%) are recommending CLLS as a Buy, 0 (0%) are recommending CLLS as a Hold, 0 (0%) are recommending CLLS as a Sell, and 0 (0%) are recommending CLLS as a Strong Sell.
What is CLLS's earnings growth forecast for 2025-2025?
(NASDAQ: CLLS) Cellectis Sa's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 9.68%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.82%.
Cellectis Sa's earnings in 2025 is -$60,532,000.
In 2025, CLLS is forecast to generate -$37,590,914 in earnings, with the lowest earnings forecast at -$37,590,914 and the highest earnings forecast at -$37,590,914.
What is CLLS's forecast return on equity (ROE) for 2025-2028?
(NASDAQ: CLLS) forecast ROE is -8.71%, which is considered weak.
What is CLLS's Price Target?
According to 1 Wall Street analyst that have issued a 1 year CLLS price target, the average CLLS price target is $4.00, with the highest CLLS stock price forecast at $4.00 and the lowest CLLS stock price forecast at $4.00.
The Wall Street analyst predicted that Cellectis Sa's share price could reach $4.00 by May 13, 2026. The average Cellectis Sa stock price prediction forecasts a potential upside of 151.57% from the current CLLS share price of $1.59.
What is CLLS's Earnings Per Share (EPS) forecast for 2025-2025?
(NASDAQ: CLLS) Cellectis Sa's current Earnings Per Share (EPS) is -$0.67. In 2025, CLLS's EPS is forecast to hit -$0.52 (min: -$0.52, max: -$0.52).
What is CLLS's forecast return on assets (ROA) for 2025-2028?
(NASDAQ: CLLS) forecast ROA is -2.78%, which is lower than the forecast US Biotechnology industry average of 44.43%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.